OSUR

Over the past six months, OraSure Technologies' stock experienced several notable events. In Q3 2025, management described 2025 as a transition year and projected a return to growth in 2026. The 52-week low stock price for OSUR was $2.08 on November 21, 2025. The company held earnings conference calls for Q4 2025 and Q1 2026. OraSure reported Q1 2026 net revenues of $27.9 million, a 7% decrease year-over-year, and missed consensus EPS estimates by $0.08. The company returned $20 million of capital to shareholders through share repurchases. Management expects mid-year FDA clearances and commercial launches for its CT/NG rapid molecular OTC self-test and the Colli-Pee at-home urine collection device, with revenue ramps anticipated in the second half of 2026.